Results 131 to 140 of about 14,398,598 (290)
Frontiers in ImmunologyAn appropriately designed pharmacokinetic (PK) assay that is sensitive for anti-drug antibody (ADA) impact on relevant exposure is an alternative strategy to understand the neutralizing potential of ADAs.
Gregor P. Lotz +14 more
doaj +1 more source
Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers [PDF]
Blood Advances, 2021 Sophie Paczesny +9 more
openaire +2 more sources
Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer
Molecular Oncology, EarlyView.Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba +5 more
wiley +1 more source
Engineering IL‐4 resistant proinflammatory human myeloid cells for cancer immunotherapy
Molecular Oncology, EarlyView.We developed a scalable workflow to generate proinflammatory human myeloid cells. CRISPR/Cas9‐edited CD34+ hematopoietic stem and progenitor cells were expanded and differentiated with M‐CSF. Deletion of STAT6 or STAT6/NFKB1 enhanced macrophage proinflammatory gene expression and cytokine secretion in the presence of IL‐4 while maintaining antibody ...
Theresa Barberi, Alan D. Friedman
wiley +1 more source
FEBS Open Bio, EarlyView.RoboMic is an automated confocal microscopy pipeline for high‐throughput functional imaging in living cells. Demonstrated with fluorescence recovery after photobleaching (FRAP), it integrates AI‐driven nuclear segmentation, ROI selection, bleaching, and analysis.
Selçuk Yavuz +6 more
wiley +1 more source
Identifying Biomarkers for Treatment of Uveal Melanoma by T cell Engager Using a QSP Model
This repository contains the QSP platform for treatment of uveal Melanoma by T cell engager developed by the Popel Systems Biology Laboratory. https://popellab.johnshopkins.edu/.THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE.
Anbari, S (via Mendeley Data)
core +1 more source
P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy
mAbsTargeting various combinations of tumor antigens and immune cell receptors is of increasing importance in antibody-based cancer immunotherapy. Here, we present a novel modular P329G-engager platform that enables rapid combination of primary tumor ...
Marlena Surowka +16 more
doaj +1 more source
Mechanistic insights into resistance mechanisms to T cell engagers
Frontiers in ImmunologyT cell engagers (TCEs) represent a groundbreaking advancement in the treatment of B and plasma cell malignancies and are emerging as a promising therapeutic approach for the treatment of solid tumors. These molecules harness T cells to bind to and eliminate cancer cells, effectively bypassing the need for antigen-specific T cell recognition.
Linlin Cao +4 more
openaire +3 more sources
Small RNA pathways in mammalian oocytes
FEBS Open Bio, EarlyView.Three distinct small RNA pathways operate in mammalian oocytes: RNAi interference (RNAi), the microRNA (miRNA) pathway, and the PIWI‐associated RNA (piRNA) pathway. These pathways use small RNAs to guide sequence‐specific repression and contribute to oocyte biology by targeting genes and mobile elements or appear insignificant since different ...
Petr Svoboda, Josef Pasulka
wiley +1 more source
, 2023 reservedGraft-versus-Host Disease (GvHD) is a life-threating immune disorder that follows hematopoietic cell transplantation. GvHD is characterized by the activation of donor immune cells targeting the recipient's healthy tissues. One of the inflammatory
PAOLUCCI, FRANCESCA
core